Navigation Links
AddBIO: Clinical Results - Implants With Bisphosphonate Show Improved Stability
Date:2/16/2012

STOCKHOLM, February 16, 2012 /PRNewswire/ --

AddBIO AB, a subsidiary of Accelerator Nordic AB, has developed Zolidd®, a proprietary bioactive nanolayer for orthopedic and dental implants that releases bisphosphonate, a bone strengthening drug. A randomized clinical trial, conducted at Linköping University Hospital, Sweden, shows that dental implants with a bisphosphonate nanolayer have improved stability.

Millions of people worldwide have dental implants, i.e. screws inserted to support artificial teeth. The first time after surgery, the implant is often not stable enough to enable chewing. It may take several months for the bone around the implant to heal and become strong enough for the patient to regain normal chewing function.

"The study shows that local bisphosphonate improves implant stability, meaning that the time until normal chewing function could be shortened, thus reducing the suffering for the patient," says Professor Per Aspenberg, Linköping University Hospital, co-founder of AddBIO.

Zolidd is the first application from a platform technology designed for local release of drugs from medical implants, developed by Professors Per Aspenberg and Penti Tengvall, Linköping University. A nanometer-thin protein layer is attached to the metal surface and a bisphosphonate is attached to the protein. When the bisphosphonate is released, a local effect is obtained, which improves implant stability. In the present study, a Zolidd prototype was used to release bisphosphonate in this way.

Sixteen patients each received two implants, one with bisphosphonate and one without. After six months, the bisphosphonate treated implant showed improved stability in 15 out of 16 patients. On x-rays, the treated implants showed positive effects already after two months. No complications occurred.

"This is an important study. With these results, we are now ready to take the next step in commercializing Zolidd," says Dr. Trine Vikinge, CEO AddBIO.

The study was conducted by Jahan Abtahi, Department of Experimental and Clinical Medicine, Faculty of Health Science, Linköping University, supported by Per Aspenberg. It has now been published online in BONE (http://dx.doi.org/10.1016/j.bone.2012.02.001).

Accelerator Nordic AB  is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator's subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, http://www.acceleratorab.se.

For additional information, contact Andreas Bunge, CEO Accelerator Nordic AB, +46-70-824-25-25.



'/>"/>
SOURCE Accelerator Nordic AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):